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Abstract
Arsenic (+3 oxidation state) methyltransferase (AS3MT) is the key enzyme in the pathway for
methylation of arsenicals. A common polymorphism in the AS3MT gene that replaces a threonyl
residue in position 287 with a methionyl residue (AS3MT/M287T) occurs at a frequency of about
10% among populations worldwide. Here, we compared catalytic properties of recombinant
human wild-type (wt) AS3MT and AS3MT/M287T in reaction mixtures containing S-
adenosylmethionine, arsenite (iAsIII) or methylarsonous acid (MAsIII) as substrates and
endogenous or synthetic reductants, including glutathione (GSH), a thioredoxin reductase (TR)/
thioredoxin (Trx)/NADPH reducing system, or tris (2-carboxyethyl) phosphine hydrochloride
(TCEP). With either TR/Trx/NADPH or TCEP, wtAS3MT or AS3MT/M287T catalyzed
conversion of iAsIII to MAsIII, methylarsonic acid (MAsV), dimethylarsinous acid (DMAsIII), and
dimethylarsinic acid (DMAsV); MAsIII was converted to DMAsIII and DMAsV. Although neither
enzyme required GSH to support methylation of iAsIII or MAsIII, addition of 1 mM GSH
decreased Km and increased Vmax estimates for either substrate in reaction mixtures containing
TR/Trx/NADPH. Without GSH, Vmax and Km values were significantly lower for AS3MT/
M287T than for wtAS3MT. In the presence of 1 mM GSH, significantly more DMAsIII was
produced from iAsIII in reactions catalyzed by the M287T variant than in wtAS3MT-catalyzed
reactions. Thus, 1 mM GSH modulates AS3MT activity, increasing both methylation rates and
yield of DMAsIII. AS3MT genotype exemplified by differences in regulation of wtAS3MT and
AS3MT/M287T-catalyzed reactions by GSH may contribute to differences in the phenotype for
arsenic methylation and, ultimately, to differences in the disease susceptibility in individuals
chronically exposed to inorganic arsenic.
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INTRODUCTION
Enzymatically catalyzed methylation of inorganic arsenic (iAs) is the main pathway for the
metabolism of iAs (Styblo et al., 1995; Vahter 1999). Conversion of iAs to methylated
metabolites affects the distribution and retention of arsenic (As) and also produces As
species that mediate some of the toxic effects associated with iAs exposure (Chen et al.,
2011; Hughes et al., 2010; Thomas et al,. 2001). Enzymatically catalyzed methylation
transfers methyl groups from S-adenosylmethionine (AdoMet) to As to produce
monomethylarsenic (MAs), dimethylarsenic (DMAs), and trimethylarsenic (TMAs)
metabolites that contain either trivalent As (AsIII) or pentavalent As (AsV) (Cullen et al.,
1984; Challenger 1951). Strong evidence suggests that arsenic (+3 oxidation state)
methyltransferase (As3mt, EC 2.1.1.137) is the key enzyme catalyzing reactions that form
all known methylated oxyarsenical metabolites of iAs (Lin et al., 2002; Thomas et al.,
2007). Two pathways have been proposed for As3mt-catalyzed methylation of iAs (Figure
1). The oxidative methylation pathway proposed by Challenger involves oxidative addition
of a methyl group to a trivalent arsenical to yield a methylated product containing
pentavalent As (Challenger 1951). The pentavalent arsenical is then reduced to trivalency
allowing repeated cycles of oxidative methylation. Coupled rounds of oxidative methylation
of trivalent As and reduction of pentavalent As converts arsenite (iAsIII) to methylarsonic
acid (MAsV), methylarsonous acid (MAsIII), dimethylarsinic acid (DMAsV),
dimethylarsinous acid (DMAsIII), trimethylarsine oxide (TMAsVO), and finally,
trimethylarsine (TMAsIII). Hirano and associates have proposed a reductive methylation
pathway in which trivalent arsenicals bound to glutathione (GSH) or a protein thiol are
substrates for repeated rounds of enzymatically catalyzed methylation (Hayakawa et al.,
2005). In this pathway, methylated trivalent arsenicals remain bound to thiols throughout the
cycle and pentavalent methylated arsenicals are produced by oxidation of AsIII-thiol
complexes. Consistent with either mechanism, both trivalent and pentavalent inorganic and
methylated arsenicals have been detected in urine of individuals chronically exposed to iAs,
in cells and medium following in vitro exposure to arsenicals, and in reaction systems that
contain recombinant As3mt (Del Razo et al., 2001, 2011; Devesa et al., 2004; Hernández-
Zavala et al., 2008; Valenzuela et al., 2005).
Previous studies of kinetic aspects and cofactor requirements for methylation reactions
catalyzed by recombinant rat As3mt (rAs3mt) found that catalysis was supported by
endogenous dithiol reductants, thioredoxin (Trx), glutaredoxin, or lipoic acid (Waters et al.
2004a,b). Thus, incorporation of coupled systems consisting of thioredoxin reductase (TR),
thioredoxin (Trx), and NADPH, or glutaredoxin/GSH/GSH reductase/NADPH, or lipoic
acid/TR/NADPH into reaction mixtures supported rAs3mt-catalyzed methylation of iAsIII to
yield mono-, di-and trimethylated arsenicals, including MAsV, MAsIII, DMAsV, DMAsIII,
TMAsVO and TMAsIII. Synthetic reductants, dithiothreitol (DTT) and tris(2-carboxylethyl)-
phosphine hydrochloride (TCEP), also supported rAs3mt-catalyzed methylation. Although
the monothiol reductant GSH did not support rAs3mt-catalyzed methylation of iAsIII and
inhibited conversion of DMAs to TMAsVO and trimethylarsine, its addition to reaction
mixtures that also contained endogenous dithiol reductants or synthetic reductants increased
methylation rates and DMAs yield. Studies with recombinant human AS3MT (hAS3MT)
have also examined kinetic aspects of As methylation and the role of reductants in catalysis
(Hayakawa et al. 2005; Song et al., 2009, 2010; Wood et al., 2006). Reductants evaluated
with hAS3MT include monothiols (mercaptoethanol, cysteine, GSH) and a dithiol DTT.
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Reactions catalyzed by hAS3MT in the presence of DTT yielded high DMAs/MAs ratios
that were similar to the ratios of these metabolites found in urine of humans ingesting iAs or
in primary cultures of human hepatocytes exposed to iAs. In contrast, reaction mixtures
containing hAS3MT and GSH as the sole reductant displayed low methylation rates, high
MAs levels, and low DMAs/MAs ratios. Thus, hAS3MT and rAs3mt are absolutely
dependent on a dithiol reductant for optimal activity. For both rAs3mt and hAS3MT, it is
likely that GSH acts as modulator, not a primary determinant, of catalytic activity.
Because the catalytic activity of hAS3MT in presence of endogenous dithiol reductants has
not been systemically examined, we characterized the function of two commonly occurring
forms of hAS3MT. These are wildtype form (wtAS3MT) which contains a methionyl
residue in position 287 and a variant form AS3MT/M287T in which this methionyl residue
is replaced by a threonyl residue. This change arises from a single nucleotide C14458T
polymorphism (rs11191439) in the coding region of AS3MT (NM_020682.3: c.860T>C)
and occurs in ~10% of Caucasian, African American and Latino populations (Del Razo, et
al., 2011; Wood et al., 2006). Individuals with wtAS3MT and AS3MT/M287T genotypes
display different urinary profiles of methylated metabolites of iAs, including changes in the
DMAs/MAs ratio (Agusa et al., 2009; Chung et al., 2009; Engström et al., 2007, 2011;
Fujihara et al., 2009; Hernández et al., 2008a,b; Hwang et al., 2010; Valenzuela et al., 2009),
suggesting that AS3MT genotype and As methylation phenotype can be linked. Therefore,
we have compared the kinetics of As methylation in reactions catalyzed by recombinant
wtAS3MT and AS3MT/M287T using physiological and synthetic reductants and examined
the role of GSH as a modulator of catalytic activities of wtAS3MT and AS3MT/M287T.
Differences in kinetic behavior of the wildtype protein and its common variant, particularly




Arsenicals used as substrates for kinetic studies or as analytical standards included iAsIII
(NaAsIIIO2), sodium arsenate (Na HAsV 2 O4) (Sigma-Aldrich, St. Louis, MO), MAsV [CH
AsV 3 O(ONa)2] and DMAsV [(CH ) V 3 2As O(OH)] (Chem Service, West Chester, PA).
These commercial reagents were stated to be greater than 98% pure. MAsIII [(CH AsIII 3
O)4], DMAsIII [(CH ) III 3 2As I], and TMAsVO were provided by Dr. William Cullen
(University of British Columbia, Vancouver, Canada). Arsenic content of each arsenical was
determined by graphite furnace-atomic absorption spectrometry (AAS) (Matoušek et al.,
2008). To minimize oxidation of unstable MAsIII and DMAsIII, fresh solutions of these
arsenicals were prepared shortly before each experiment.
Expression and Purification of Human Recombinant wtAS3MT and AS3MT/M287T
Human wtAS3MT DNA was PCR amplified from normal human liver cDNA (Invitrogen,
Carlsbad, CA). The PCR product was cloned into the pRSET expression vector (Invitrogen).
The AS3MT/T860C mutant that encodes the AS3MT/M287T variant was generated using
the QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies, Inc., Santa Clara,




. Identity and orientation of the wtAS3MT and AS3MT/T860C inserts in expression vectors
were confirmed by sequencing. His-tagged wtAS3MT and AS3MT/M287T proteins were
expressed in BL21(DE3)pLysS E. coli strain (Bioline, Tauton, MA) and purified by Ni-NTA
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agarose following the manufacturer’s instructions (Qiagen, Valencia, CA). Identity and
purity of purified proteins were confirmed by gel electrophoresis with Coomassie Blue
staining and by immunoblots using a mouse monoclonal anti-His antibody (Qiagen,
Valencia, CA) and a rabbit polyclonal anti-human AS3MT antibody (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) (Figure S1, Supplementary Data). Protein
concentrations were measured using a BCA kit from Sigma-Aldrich with bovine serum
albumin as a standard. Purified proteins were aliquoted and stored at −80°C until use.
In Vitro Methylation Assay
Catalytic activities of wtAS3MT and AS3MT/M287T were examined in reaction mixtures
that contained 100 mM Tris-HCl buffer (pH 7.4), a recombinant enzymes (0.5 – 5 μg), 1
mM AdoMet (Sigma), an arsenical substrate, and one or several of the following reductants:
GSH (Sigma-Aldrich), TCEP (Sigma-Aldrich), recombinant rat TR (American Diagnostica,
Greenwich, CT) or TR purified from rat liver (Sigma-Aldrich), Trx from E. coli (Sigma-
Aldrich), and NADPH (Sigma-Aldrich). The final volume of the mixture was 100 μl. The
mixtures were incubated in capped 1.5-ml Eppendorf tubes at 25°C or 37°C for up to 2
hours. Michaelis-Menten constants (Km and Vmax) were calculated to determine capacity of
AS3MT variants to methylate arsenicals and their affinity for arsenical substrates.
Analysis of Products of In Vitro Methylation Reactions
Concentrations of As species in reaction mixtures were determined by oxidation state
specific hydride generation (HG)-cryotrapping (CT)- AAS as previously described
(Hernández-Zavala et al., 2008; Matoušek et al., 2008). Briefly, HG-CT-AAS measured As
contents in arsine and methyl-substituted arsines (methyl- and dimethylarsine) generated in
reactions of iAs, MAs and DMAs with sodium borohydride (EM Science, Gibbstown, NJ) at
pH 6. Arsines from trivalent arsenicals (iAsIII, MAsIII and DMAsIII) were generated
directly. For generation of arsines from both tri- and pentavalent arsenicals, the latter were
reduced with 2% cysteine hydrochloride (EMD Chemicals Inc., Gibbstown, NJ).
Concentrations of AsV-species were then calculated as a difference between the two
measurements. To prevent oxidation of unstable DMAsIII, one-half of an in vitro reaction
mixture (50 μl) was analyzed for trivalent arsenicals immediately after incubation. The
remaining sample was snap frozen in dry ice and stored at -80°C for analysis of AsIII+V
species. Limits of detection for analysis of trivalent and pentavalent iAs, MAs and DMAs
species by HG-CT-AAS ranged from 8 to 20 pg As. Percentage As recovery from a reaction
mixture was calculated by comparing sum of the tri- and pentavalent arsenicals determined
by HG-CT-AAS after incubation and the amount of substrate added into the reaction
mixture before incubation. Recoveries of As in this study ranged from 89 to 105%.
Statistical Analysis
All statistical analyses used the SAS software package (SAS Institute Inc., Cary, North
Carolina). A general linear model or one-way analysis of variance (ANOVA) with Student-
Newman-Keuls or Bonferoni correction for multiple comparisons was used to identify
statistically significant differences (p < 0.05) between rates and yields of in vitro
methylation reactions catalyzed by wtAS3MT or AS3MT/M287T. These methods were also
used to characterize differences between corresponding Km and Vmax values.
RESULTS
Effects of Reductants on Methylation of iAsIII by wtAS3MT and AS3MT/M287T
The function of GSH as a reductant was evaluated in reaction mixtures containing
recombinant wtAS3MT or AS3MT/M287T (5 μg), 1 mM AdoMet, 1 μM iAsIII and 1 to 20
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mM GSH. The mixtures were incubated for 2 hours at 37°C, treated with 2% cysteine and
analyzed by HG-CT-AAS for presence of total iAs (iAsIII + iAsV), total MAs (tMAs =
MAsIII + MAsV), total DMAs (tDMAs = DMAsIII + DMAsV). In the presence of 1 mM
GSH as the sole reductant, both wtAS3MT and AS3MT/M287T catalyzed conversion of less
than 1% of substrate to tMAs and tDMAs (Figure 2A). Although methylation yields
increased proportionally in the presence of 5 and 10 mM GSH, tMAs, not tDMAs, was the
major metabolite. In contrast, addition of 20 mM GSH sharply inhibited methylation
catalyzed by either protein. Addition of 1 mM TCEP or coupled system consisting of 0.2
μM TR, 10 μM Trx and 300 μM NADPH to reaction mixtures containing wtAS3MT or
AS3MT/M287T supported iAsIII methylation (Figure 2B). For either protein, about 45% and
90% of iAsIII was methylated over the 2-hour incubation period in the presence of TCEP
and TR/Trx/NADPH, respectively. For either reductant and either protein, tDMAs
accounted for more than 95% of methylated product.
Modulation by GSH of iAsIII Methylation Catalyzed by wtAS3MT or AS3MT/M287T
The effect of GSH on methylation of iAsIII was examined in reaction mixtures that
contained 1 μM iAsIII, wtAS3MT or AS3MT/M287T (5 μg), and TR/Trx/NADPH coupled
system. Reaction mixtures were incubated at 37°C for up to 40 minutes and yields of tri-and
pentavalent methylated metabolites were determined by HG-CT-AAS. Without added GSH,
profiles of metabolites were similar in reactions catalyzed by wtAS3MT or AS3MT/M287T.
Methylated arsenicals containing either AsIII or AsV; MAsIII, MAsV, DMAsIII, and DMAsV
were detected in these reaction mixtures. tDMAs yields increased in proportion to
incubation time, accounting for ~55% of total substrate at 40 minutes; DMAsIII accounted
for ~40-60% of tDMAs (Figure 3A,C). Addition of 1 mM GSH to reaction mixtures
approximately doubled yields of methylated meta bolites (Figure 3B,D). At all time points,
addition of GSH produced significantly higher yields of tDMAs in reactions catalyzed by
AS3MT/M287T than in reactions catalyzed by wtAS3MT (p < 0.05). In reactions catalyzed
by either protein in the presence of GSH, DMAsIII was the predominant metabolite,
accounting for >90% tDMAs. The 10-, 20-and 30-minute DMAsIII yields were significantly
higher in reactions catalyzed by AS3MT/M287T as compared to wtAS3MT-catalyzed
reactions (p < 0.05). In reaction mixtures that contained TCEP as reductant, addition of GSH
also increased methylation rates and DMAsIII yields (Figure S2, Supplementary Data).
Notably, methylation rates in TCEP-supported reactions were lower than methylation rates
in reaction mixtures containing TR/Trx/NADPH.
Effect of iAsIII Concentration on wtAS3MT and AS3MT/M287T Activities
Rates and yields of wtAS3MT-or AS3MT/M287T-catalyzed reactions were examined with
or without GSH in reaction mixtures that contained 0.25 to 4 μM iAsIII and TR/Trx/NADPH
(Figure 4). Methylation rates increased proportionally with iAsIII concentration for both
wtAS3MT-and AS3MT/M287T-catalyzed reactions. In the absence of GSH, DMAsIII and
DMAsV were major metabolites; DMAsIII accounted for ~40-60% of tDMAs. At all
substrate concentrations, MAsIII and MAsV were minor metabolites. At 0.25 to 0.5 μM
iAsIII, the AS3MT/M287T-catalyzed reactions generated significantly more tMAs than
reactions catalyzed by wtAS3MT. Addition of 1 mM GSH to reaction mixtures with either
enzyme increased methylation rates 2-to 3-fold and increased the fraction of tDMAs present
as DMAsIII. Addition of 1 mM GSH to reaction mixtures with either enzyme significantly
increased tMAs production in reaction mixtures at low substrate (≤ 1 μM) concentrations.
However, with added GSH, AS3MT/M287T-catalyzed reactions at low substrate (≤ 1 μM)
concentrations yielded tDMAs and DMAsIII at significantly higher rates than did
wtAS3MT-catalyzed reactions. Catalytic efficiencies of wtAS3MT and AS3MT/M287T
were compared using tDMAs/tMAs ratios for either enzyme in the absence or presence of
GSH (Figure 5). Without added GSH, tDMAs/tMAs ratios for both enzymes remained low
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and varied only about 2-fold over the range of substrate concentrations. For both enzymes,
addition of GSH to reaction mixtures increased tDMAs/tMAs ratios over the range of
substrate concentrations. The stimulatory effect of GSH was greatest for 1 and 2 μM iAsIII.
At 2 μM iAsIII, tDMAs/tMAs ratios for the enzymes differed significantly (p < 0.05).
Similar concentration-dependent increases in tDMA and DMAsIII production were found in
wtAS3MT- or AS3MT/M287T-catalyzed reactions that contained 1 mM TCEP as reductant
(Figure S3, Supplementary Data). Although tDMA and DMAsIII production rates were
lower in the presence of TCEP than of TR/Trx/NADPH, addition of 1 mM GSH stimulated
both tMAs and tDMAs production that resulted in decreased tDMAs/tMAs ratios in the
methylation reaction when TCEP as reductant (results not shown). In the absence and
presence of GSH rates of tMAs and tDMAs production were generally higher in AS3MT/
M287T-catalyzed reactions than in wtAS3MT -catalyzed reactions.
Methylation of MAsIII by wtAS3MT and AS3MT/M287T
Methylation of MAsIII (0.25 – 4 μM) was examined in reaction mixtures containing
recombinant wtAS3MT or AS3MT/M287T and a TR/Trx/NADPH coupled system as
reductant. The mixtures were incubated at 37°C. Because rates of MAsIII methylation
catalyzed by either AS3MT protein much exceeded iAsIII methylation rates, assay
conditions were modified to use less protein (1 μg). Both DMAsIII and DMAsV were
products of MAsIII methylation (Figure 6). Rates of wtAS3MT- and AS3MT/M287T-
catalyzed reactions increased over the 0.25 to 1 μM MAsIII concentration range but
remained unchanged or declined at higher concentrations suggesting substrate inhibition.
Addition of 1 mM GSH to reaction mixtures increased rates of MAsIII methylation and
DMAsIII yields for both proteins (p < 0.05). At MAsIII concentrations ≤ 2 μM, reaction rates
in wtAS3MT- or AS3MT/M287T-catalyzed reactions were equally stimulated by GSH. In
reaction mixtures that contained 4 μM MAsIII, addition of GSH resulted in significantly
higher (p < 0.05) rates of both tDMAs and DMAsIII formation in wtAS3MT-catalyzed
reactions than in AS3MT/M287T-catalyzed reactions. With 0.25 to 4 μM MAsIII in TCEP-
containing reaction mixtures, methylation profiles with or without GSH addition resembled
those found in reaction mixtures containing TR/Trx/NADPH (Figure S4, Supplementary
Data). For both proteins, tDMAs production rates in TCEP-containing reaction mixtures
were much lower than those in reaction mixtures containing TR/Trx/NADPH but were
stimulated by addition of GSH. Notably, inhibition of wtAS3MT-or AS3MT/M287T-
catalyzed methylation by 2 and 4 μM MAsIII was more pronounced in the presence of TCEP
than in the reaction mixtures containing TR/Trx/NADPH.
Michaelis-Menten Kinetics for Methylation of iAsIII and MAsIII by wtAS3MT and AS3MT/
M287T
Michaelis-Menten constants, Km and Vmax, were calculated for wtAS3MT-and AS3MT/
M287T-catalyzed methylation of iAsIII from equations characterizing double-reciprocal
plots of 1/v vs 1/[iAsIII] for iAsIII concentrations of 0.25, to 4.0 μM (Figure 7). The
reactions were carried out with 5 μg recombinant protein at 37°C. The reaction rate (v) was
expressed as pmol of CH3 groups transferred to substrate by 1 μg of recombinant enzyme in
1 minute. Double-reciprocal plots were also used to calculate Km and Vmax for methylation
of MAsIII (plots not shown). However, because MAsIII concentrations > 1.0 μM inhibited
methylation catalyzed by either enzyme, these plots were calculated from data obtained at
lower MAsIII concentrations. In the presence of TR/Trx/NADPH and the absence of GSH,
both Km and Vmax values for methylation of iAsIII were significantly lower (p<0.05) for
reactions catalyzed by AS3MT/M287T than for reactions catalyzed by wtAS3MT (Table 1).
Addition of 1 mM GSH increased Vmax values and decreased Km values for reactions
catalyzed by either enzyme. However, in the presence of GSH, Km and Vmax values for
wtAS3MT and AS3MT/M287T were not statistically different. Km and Vmax values were
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also determined for wtAS3MT-and AS3MT/M287T-catalyzed reactions using MAsIII as
substrate and 0.5 μg of recombinant protein per assay. The rate of MAsIII methylation at
37°C was significantly higher than the rate of iAsIII methylation under the same conditions.
To accurately measure the rate of MAsIII methylation during the linear phase of the reaction,
the reaction mixtures were incubated at 25°C. For MAsIII, AS3MT/M287T-catalyzed
reactions yielded a significantly higher Km value and a significantly higher Vmax value than
did a wtAS3MT-catalyzed reaction (both p < 0.05). Addition of 1 mM GSH to reaction
mixtures containing either protein increased Vmax and decreased Km values and minimized
differences between these constants in wtAS3MT-and AS3MT/M287T-catalyzed reactions.
Notably, Vmax values for MAsIII methylation catalyzed by wtAS3MT and AS3MT/M287T
both in the presence and absence of GSH were several-fold higher than corresponding Vmax
values for iAsIII methylation. The K value characterizing wtAS3MT-catalyzed activity in the
absence of GSH was higher for iAsIII (4.1 μM) than for MAsIII (1.5 μM). In contrast, the
AS3MT/M287T-catalyzed activity was characterized by a low Km for iAsIII (2.0 μM) and a
high Km for MAsIII (3.0 μM). In the presence of GSH, Km value was significantly lower for
MAsIII than for iAsIII for reactions catalyzed by wtAS3MT but not for reactions catalyzed
by AS3MT/M287T. Km and Vmax values were also calculated for iAsIII and MAsIII
methylation catalyzed by wtAS3MT and AS3MT/M287T with TCEP as reductant (Table
S1, Supplementary Data). Here, Km and Vmax values for wtAS3MT-and AS3MT/M287T-
catalyzed methylation of iAsIII in the absence of GSH were similar. Addition of 1 mM GSH
increased Vmax and decreased Km value by similar margins for both variants. Without
addition of GSH, Vmax and Km values for MAsIII methylation were higher for AS3MT/
M287T than for wtAS3MT. Addition of GSH decreased Km values for MAsIII methylation
by both AS3MT variants, but had little or no effects on Vmax values.
Examination of wtAS3MT and AS3MT/M287T Activities with Pentavalent Arsenicals
Here, the reaction mixtures containing 5 μg of recombinant protein, 1 mM AdoMet, the TR/
Trx/NADPH reducing system, and 1 μM iAsV, MAsV or DMAsV were incubated in the
presence or absence of 1 mM GSH at 37°C for 2 hours. The reaction mixtures were then
analyzed for tri- and pentavalent As species by HG-CT-AAS. None of the pentavalent
arsenicals was methylated under these conditions. However, ~0.6% of DMAsV was reduced
to DMAsIII in the absence and 7.2% in the presence of GSH. About 0.1-0.2% of MAsV was
reduced to MAsIII regardless of GSH presence.
DISCUSSION
The coupled TR/Trx/NADPH system supported methylation by two most common variants
of hAS3MT resulting in high methylation rates and high DMAs/MAs ratios in presence of
GSH. Both hAS3MT forms catalyzed reactions that converted iAsIII to MAsIII, MAsV,
DMAsIII, and DMAsV, and MAsIII to DMAsIII, and DMAsV. The arrays of metabolites
produced in reaction mixtures were consistent with those found in urine of individuals
exposed to iAs (Valenzuela et al. 2005; Del Razo et al, 2011). Unlike rAs3mt, human
wtAS3MT and AS3MT/M287T did not catalyze formation of trimethylated arsenicals.
Catalytic functions of both rAs3mt and hAS3MT are absolutely dependent on a reductant
(Hayakawa et al., 2005; Song et al., 2010; Waters et al., 2004a,b). A number of synthetic
and physiologically relevant compounds have been shown to support the catalytic activity of
both rAs3mt and hAS3MT. The TR/Trx/NADPH system has been most effective in
supporting the rAs3mt activity (Waters et al., 2004a,b), but has never been tested as a
cofactor of hAS3MT. Although GSH, the most abundant low-molecular weight reductant in
mammalian cells, did not support catalysis by rAs3mt (Waters et al., 2004a,b), it did support
methylation of iAsIII catalyzed by hAS3MT (Hayakawa et al., 2005; Song et al., 2010).
However, with GSH as the sole reductant, rates of hAS3MT-catalyzed methylation were low
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and MAs, not DMAs, was the prime metabolite. The current study examined reductant
requirements of the most common variants of hAS3MT and found that Trx fully supported
hAS3MT catalysis. In contrast, GSH was neither necessary nor sufficient to support
catalysis by hAS3MT but did modulate the amount and pattern of metabolites. Notably, the
in vitro assay conditions used in the present study (the enzyme:substrate ratio, AdoMet and
GSH concentrations, pH and temperature) were comparable to those used in previous studies
examining iAs methylation by either rAs3mt (Waters et al., 2004a,b) or hAS3MT
(Hayakawa et al., 2005; Song et al., 2010).
Catalytically active vicinal cysteines in TR that reduce protein disulfides may reduce highly
conserved cysteinyl residues in rAs3mt and hAS3MT that are required for catalytic activity
(Sun et al., 1999; Thomas et al, 2007). The targets for reduction by TR could be disulfides
generated during oxidative methylation of trivalent As or reduction of pentavalent As to
trivalency. TR-coupled arsenate reductases have been identified in several prokaryotes
(Messens and Silver 2006). For example, TR is oxidized in the reduction of a disulfide
between critical cysteinyl residues in a TR-dependent ArsC arsenate reductase (Roos et al.,
2009). A possible linkage between As methylation and the role of TR in AS3MT catalysis
occurs through production of MAsIII, a competitive inhibitor of Trx (Ki ~ 100 nM) (Lin et
al., 1999). Exposure of cultured primary rat hepatocytes to MAsIII inhibits TR activity and
reduces capacity to methylate iAs (Lin et al, 2001). Thus, in the cellular environment,
production of methylated metabolites of iAs catalyzed by AS3MT could be modulated by
the availability of TRx which is regulated by the TR activity.
In reaction mixtures containing TR/Trx/NADPH or TCEP, GSH modulated hAS3MT
activity. The physiological concentration of 1 mM GSH increased overall methylation rates
and DMAs/MAs ratio. With added 1 mM GSH, metabolites formed from iAsIII and MAsIII
were almost exclusively trivalent methylated arsenicals (MAsIII and DMAsIII). The
predominance of trivalent arsenicals could reflect GSH-dependent reduction of pentavalent
As to trivalency and formation of stable complexes of GSH and trivalent arsenicals. In
addition, complexes of trivalent arsenicals and GSH may serve as substrates for reactions
catalyzed by rat As3mt (Waters et al., 2004b) and human AS3MT (Hayakawa et al., 2005).
However, the HG-CT-AAS method used in this study cannot differentiate between free
trivalent arsenicals and arsenical-GSH complexes and thus, cannot inform on the mechanism
(oxidative vs. reductive) of the methylation reactions. Studies with an AsIII S-
adenosylmethionine methyltransferase from the thermophilic eukaryotic alga
Cyanidioschyzon sp. 5508 (CmArsM) that is orthologous with hAS3MT show that the
substrate-GSH complexes iAsIII(GS)3 and MAsIII-(GS)2 are preferred substrates for
methylation (Marapakala et al., 2012). Notably, the present study found that even in the
presence of a one-thousand fold molar excess of GSH, iAsV, MAsV, or DMAsV were not
substrates for methylation by either hAS3MT form. This suggests that neither GSH-
dependent reduction of pentavalent arsenicals nor complexation of resulting trivalent
arsenicals by GSH was sufficient to provide substrates used for methylation reactions
catalyzed by this enzyme. Alternatively, GSH could modulate the activity of hAS3MT by
glutathionylation, the formation of mixed disulfides between GSH and protein cysteinyl
residues. Glutathionylation of critical cysteinyls in hAS3MT could regulate protein function
(Gallogly and Mieyal 2007) by affecting interactions between these residues that contribute
to the protein’s catalytic function. Thus, an extensive glutathionylation could be also
responsible for the inhibition of AS3MT activity in the reaction assays containing 20 mM
GSH (Figure 1).
This study characterized catalysis of As methylation by two major variants of human
AS3MT, wtAS3MT and AS3MT/M287T. Differences between the catalytic properties of
these two variants depended specifically on presence of GSH in reaction mixtures. Thus, in
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the presence of TR/Trx/NADPH and GSH, AS3MT/M287T produced more DMAsIII and
tDMAs from iAsIII than did wtAS3MT. Although this difference was small, it was
statistically significant over the substrate range of 0.25 to 1 μM iAsIII. No differences in
DMAsIII and tDMAs yields were found for higher iAsIII concentrations (2 and 4 μM),
indicating that the catalytic capacities of both variants were saturated. Consistent with
saturation of the second methylation step (i.e., the conversion of MAs to DMAs) was also
the sharp increase in MAs yield found in reaction mixture containing 4 μM iAsIII (Figure
4B,D). In contrast, when MAsIII was used as the substrate, tDMAs or DMAsIII production
by the AS3MT variants did not differ except at 4 μM MAsIII. This suggests that the two
methylation reactions catalyzed by the enzyme are not equivalent in terms of modulation by
GSH. The non-equivalency of mono-and dimethylation reactions was also partly reflected
by differences in Km and Vmax values obtained with different arsenical substrates.
Comparison of wtAS3MT and AS3MT/M287T in reaction mixtures with iAsIII and TR/Trx/
NADPH found lower Km and Vmax values for AS3MT/M287T; this is consistent with a
higher affinity but a lower capacity for methylation of substrate in AS3MT/M287T-
catalyzed reactions in absence of GSH. In reaction mixtures with MAsIII and TR/Trx/
NADPH in absence of GSH, the affinity of wtAS3MT was higher than that of AS3MT/
M287T, but the capacity to methylate MAsIII was lower. Addition of GSH to reaction
mixtures containing TR/Trx/NADPH increased Vmax and decreased Km values and
minimized differences between Km and Vmax values in wtAS3MT-and AS3MT/M287T-
catalyzed reactions.
The ratio of tDMAs/tMAs in urine has been used as a heuristic indicator of methylation
capacity of individuals exposed to iAs and in studies of interindividual variability in
susceptibility to adverse health effects associated with chronic iAs exposure. Several
previous studies have linked the AS3MT/M287T polymorphism with lower tDMAs/tMAs
ratios or higher percentage of MAs in urine (Engström et al., 2007, 2011; Hernández et al.,
2008a,b; Lindberg et al., 2007; Valenzuela et al., 2009) and with evidence of increased
susceptibility to the toxic effects of iAs (Drobná et al., 2012; Hernández and Marcos, 2008;
Sampayo-Reyes et al., 2010; Valenzuela et al., 2009). From these findings, investigators
posited that the M287T polymorphism modifies the kinetics of AS3MT-catalyzed
methylation so that the concentration of the intermediate tMAs increases relative to the
concentration of tDMAs. However, the present study of wtAS3MT and AS3MT/M287T-
catalyzed methylation reactions found that the M287T polymorphism had little effect on
tDMAs/tMAs ratios. tDMAs/tMAs ratios for wtAS3MT and AS3MT/M287T-catalyzed
methylation reactions differed significantly only in reactions containing 2 μM iAsIII and 1
mM GSH (Figure 5). The lack of a consistent effect of genotype on the methylation capacity
of AS3MT indicates that differences in the catalytic efficiences of wtAS3MT and AS3MT/
M287T do not fully account for differences in tDMAs/tMAs ratios in urine. It is likely that
processes affecting the binding and retention of methylated arsenicals in tissues that occur
between AS3MT-catalyzed methylation and excretion of methylated metabolites in urine
also influence the ratios of these metabolites in urine. A recent genome wide association
study supports the concept that multiple genetically determined aspects of iAs metabolism
could contribute to the both metabolic and toxicity phenotypes (Pierce et al., 2012). Among
these modifiers of arsenic metabolism could be interindividual variation in the control of
GSH metabolism. Altered GSH availability could modulate the catalytic activities of both
wtAS3MT and AS3MT/M287T.
Although TCEP, a synthetic non-thiol reductant, also supported the AS3MT-catalyzed
methylation of iAsIII and MAsIII, lower rates of conversion were found with this reductant
than with TR/Trx/NADPH. Notably, addition of GSH to reaction mixtures containing either
TR/Trx/NADPH or TCEP as reductant evoked similar changes in the pattern of metabolites
and in the kinetic properties of reactions catalyzed by either form of hAS3MT. This suggests
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that the modulatory action of GSH did not depend upon a specific interaction between
reductant and GSH but rather upon its independent effect on catalysis by the protein.
Understanding the distinct roles of dithiol reductants and GSH in control of catalysis by
hAS3MT will depend on elucidating the structure of the enzyme and the molecular basis of
methylation and substrate reduction processes that it catalyses.
In summary, this study found that a common polymorphism in the hAS3MT gene was
associated with differences in the pattern of methylated metabolites generated in reaction
mixtures that contained a dithiol reductant and variant forms of the enzyme. This provides a
plausible biochemical link between hAS3MT genotype and As methylation phenotype as
reflected by the pattern of arsenical metabolites in urine (Engstrom et al., 2011). This
relation between hAS3MT genotype and phenotype can be extended to a disease
susceptibility phenotype. Statistically significant increases in risk of skin lesions or of
carotid atherosclerosis have been associated with the AS3MT/M287T polymorphism (Hsieh
et al., 2011; Valenzuela et al., 2009) and in children with susceptibility to DNA damage
(Sampayo-Reyes et al., 2010). Similarly, individuals with AS3MT/M287T polymorphisms
were more likely than wtAS3MT carriers to be diagnosed with diabetes in our recent study
in the Zimapan and Lagunera regions (Mexico) where residents are exposed to iAs in
drinking water (Del Razo et al., 2011). Consistent with results of the present study, carriers
of AS3MT/M287T had higher levels of DMAsIII in urine (Drobná et al., 2012). Taken
together, this data suggest that increased production of DMAsIII is at least in part
responsible for an increased susceptibility of AS3MT/M287T carriers to chronic iAs
toxicity. Thus, understanding the molecular basis of variation in capacity for AS3MT-
catalyzed conversion of iAs into its methylated metabolites is a first step in linking genotype
to phenotypic variation in disease susceptibility and better evaluation of risk associated with
exposure to this metalloid.
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• Human AS3MT and AS3MT(M287T) require a dithiol reductant for optimal
activity.
• Both enzymes methylate arsenite to tri- and pentavalent methylated metabolites.
• Neither enzyme requires glutathione (GSH) to methylate arsenite or
methylarsonite.
• However, in presence of a dithiol addition of 1mM GSH increases methylation
rates.
• In presence of 1mM GSH, AS3MT(M287T) produces more dimethylarsinite
than AS3MT.
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Two postulated pathways for methylation of inorganic arsenic by AS3MT: A. Oxidative
methylation pathway; B. Reductive methylation pathway; iAsIII, arsenite; MAsV,
methylarsonic acid; MAsIII, methylarsonous acid, DMAsV, dimethylarsinic acid; DMAsIII,
dimethylarsinous acid; TMAsV, trimethylarsine oxide; TMAsIII, trimethylarsine; AdoMet,
S-adenosylmethionine; AdoHcy, S-adenosylhomocysteine; GSH, glutathione; e, electron.
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Effects of reductants on methylation of arsenite (iAsIII) by wtAS3MT and AS3MT/M287T.
Reaction mixtures contained 100 mM Tris-HCl buffer (pH 7.4), recombinant enzyme (5
μg), 1 mM AdoMet, 1 μM iAsIII and one of the following reductants or reducing systems:
A. GSH (1, 5, 10 or 20 mM); B. 1 mM TCEP or a coupled enzymatic system consisting of
0.2 μM TR, 10 μM Trx and 300 μM NADPH. Reaction mixtures were incubated at 37°C
for 2 hours. Cumulative yields of tMAs (MAsIII + MAsV) and tDMAs (DMAsIII + DMAsV)
shown (Mean ± SD, n = 3).
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Effects of glutathione (GSH) on methylation of arsenite (iAsIII) catalyzed by wtAS3MT or
AS3MT/M287T in the presence of TR/Trx/NADPH. Reaction mixtures contained 100 mM
Tris-HCl buffer (pH 7.4), recombinant enzyme (5 μg), 1 mM AdoMet, 1 μM iAsIII, 0.2 μM
TR, 10 μM Trx, 300 μM NADPH, and either 0 mM GSH (A,C) or 1 mM GSH (B,D).
Reactions mixtures were incubated at 37°C for up to 40 minutes. Yields of MAsIII tMAs,
DMAsIII and tDMAs are shown as mean ± SD for n = 3. (Note that the SD bars for all time
points are smaller than the symbols marking the corresponding mean values.)
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Effect of glutathione (GSH) on rates of wtAS3MT and AS3MT/M287T-catalyzed
methylation of arsenite (iAsIII). Reaction mixtures contained 100 mM Tris-HCl buffer (pH
7.4), recombinant enzyme (5 μg), 1 mM AdoMet, 0.2 μM TR, 10 μM Trx, 300 μM
NADPH, iAsIII (0.25, 0.33, 0.5, 1, 2 or 4 μM), and either 0 mM GSH (A, C, E, G) or 1 mM
GSH (B, D, F, H). Reaction mixtures were incubated at 37°C for 20 minutes. The rates of
tMAs, MAsIII, tDMAs and DMAsIII production (ng As/μg protein/hour) shown (Mean ±
SD, n = 3). *Rates of methylation by wtAS3MT and AS3MT/M287T are significantly
different (p < 0.05).
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Effects of arsenite (iAsIII) concentration and glutathione (GSH) on tDMAs/tMAs ratio.
Reaction mixtures contained 100 mM Tris-HCl buffer (pH 7.4), recombinant enzyme (5
μg), 1 mM AdoMet, 0.2 μM TR, 10 μM Trx, 300 μM NADPH, iAsIII (0.25, 0.33, 0.5, 1, 2
or 4 μM) and either 0 or 1 mM GSH. Reaction mixtures were incubated at 37°C for up to 20
minutes. tDMAs/tMAs ratios shown (Mean ± SD, n = 3). *Denotes a significant difference
(p < 0.05) between tDMAs/tMAs ratios for reactions catalyzed by wtAS3MT and AS3MT/
M287T.
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Effect of glutathione (GSH) on methylation of methylarsonous acid (MAsIII) by wtAS3MT
and AS3MT/M287T. Reaction mixtures contained 100 mM Tris-HCl buffer (pH 7.4),
recombinant enzyme (1 μg), 1 mM AdoMet, 0.2 μM TR, 10 μM Trx, 300 μM NADPH,
MAsIII (0.25, 0.33, 0.5, 1, 2 or 4 μM) and either 0 or 1 mM GSH. Reaction mixtures were
incubated at 37°C for up to 60 minutes in the absence of GSH (A,C) and for up to 30
minutes in the presence of GSH (B,D). Rates of tDMAs (A,B) and DMAsIII (C,D)
production (ng As/μg protein/hour) shown (Mean ± SD, n = 3). *wtAS3MT-and AS3MT/
M287T-catalyzed rates of methylation are significantly different (p < 0.05).
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Double-reciprocal plots of 1/v vs. 1/[iAsIII] for the methylation of arsenite (iAsIII) by
wtAS3MT and AS3MT/M287T: Effects of polymorphism on double-reciprocal plots for the
methylation reactions in the presence (A) or absence (B) of 1 mM GSH, and effects of 1
mM GSH on double-reciprocal plots for the methylation reactions catalyzed by wtAS3MT
(C) and AS3MT/M287T (D) (Mean ± SD, n = 3). For reaction conditions see Figure 4.
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